Enhancement of insulin signaling pathway in adipocytes by oxovanadium(IV) complexes

Biochemical and Biophysical Research Communications

Volumn 349, Issue 3, 2006, Pages 1163-1170

  Basuki, Wanny ^a   Hiromura, Makoto ^a   Adachi, Yusuke ^a   Tayama, Kojiro ^a   Hattori, Masakazu ^b   Sakurai, Hiromu ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

3T3 L1 adipocytes; Akt; GLUT4 translocation; GSK3 ; Insulin mimetic; Oxovanadium(IV) picolinate complex

Indexed keywords

GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; OXOVANADIUM; PHOSPHOTYROSINE; PICOLINIC ACID DERIVATIVE; PROTEIN KINASE B; STREPTOZOCIN; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CELL STRAIN 3T3; COMPLEX FORMATION; CONTROLLED STUDY; DRUG POTENCY; HYPERGLYCEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL MEMBRANE; DIABETES MELLITUS; GLUCOSE TRANSPORTER TYPE 4; GLYCOGEN SYNTHASE KINASE 3; HYPOGLYCEMIA; INSULIN; MALE; MICE; MOLECULAR STRUCTURE; PHOSPHORYLATION; PHOSPHOTYROSINE; PICOLINIC ACIDS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; VANADATES;

ANIMALIA;

EID: 33748709304     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.08.162     Document Type: Article

References (34)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. WHO: Definition, diagnosis and classification of diabetes mellitus and its complications report of a WHO consultation, Part 1: diagnosis and classification of diabetes mellitus, WHO Geneva (1999) 1--65.
3. Kuzuya T., Nakagawa S., Satoh J., Kanazawa Y., Iwamoto Y., Kobayashi M., Nanjo K., Sasaki A., Seino Y., Ito C., Shima K., Nonaka K., and Kadowaki T. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res. Clin. Pract. 55 (2002) 65-85
4. Saltiel A.R., and Kahn C.R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414 (2001) 799-806
5. Herman M.A., and Kahn B.B. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Invest. 116 (2006) 1767-1775
6. Taniguchi C.M., Emanuelli B., and Kahn C.R. Critical nodes in signaling pathway: insights into insulin action. Nat. Rev. Mol. Cell. Biol. 7 (2006) 85-96
7. Brazil D.P., and Hemmings B.A. Ten years of protein kinase B signaling: a hard Akt to follow. Trends Biochem. Sci. 26 (2001) 657-664
8. Kanzaki M. Insulin receptor signals regulating GLUT4 translocation and actin dynamics. Endocrinol. J. 12 (2006) 1-37
9. Olson A.L., Knight J.B., Pessin J.E., and Syntaxin 4. VAMP2, and/or VAMP3/cellubrevin are functional target membrane and vesicle SNAP receptors for insulin-stimulated GLUT4 translocation in adipocytes. Mol. Cell. Biol. 17 (1997) 2425-2435
10. Byon J.C.H., Kusari A.B., and Kusari J. Protein-tyrosine phosphatase-1B acts as anegative regulator of insulin signal transduction. Mol. Cell. Biochem. 182 (1998) 101-108
11. Srivastava A.K., and Mehdi M.Z. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabetic. Med. 22 (2004) 2-13
12. Jelveh K.A., Zhande R., and Brownsey R.W. Inhibition of cyclic AMP dependent protein kinase by vanadyl sulfate. J. Biol. Inorg. Chem. 11 (2006) 379-388
13. Carmen G.Y., and Victor S.M. Signaling mechanisms regulating lipolysis. Cell. Sig. 18 (2006) 401-408
14. Cohen N., Halberstam M., Shlimovich P., Chang C.J., Shamoon H., and Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin dependent diabetes mellitus. J. Clin. Invest. 95 (1995) 2501-2509
15. Cusi K., Cukier S., DeFronzo R.A., Torres M., Puchulu F.M., and Pereira Redondo J.C. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab. 86 (2001) 1410-1417
16. Fugono J., Yasui H., and Sakurai H. Pharmacokinetic study on gastrointestinal absorption of insulinomimetic vanadyl complexes in rats by ESR spectroscopy. J. Pharm. Pharmacol. 53 (2001) 1247-1255
17. Sakurai H. A new concept: the use of vanadium complexes in the treatment of diabetes mellitus. Chem. Rec. 2 (2002) 237-248
18. Fugono J., Yasui H., and Sakurai H. Enteric-coating capsulation of insulinomimetic vanadyl sulfate enhances bioavailability of vanadyl species in rats. J. Pharm. Pharmacol. 54 (2002) 611-615
19. Yasui H., Tamura A., Takino T., and Sakurai H. Structure-dependent metallokinetics of antidiabetic vanadyl-picolinate complexes in rats: studies on solution structure, insulinomimetic activity and metallokinetics. J. Inorg. Biochem. 91 (2002) 327-338
20. Sakurai H., and Yasui H. Structure-activity relationship of insulinomimetic vanadyl-picolinate complexes in view of their clinical use. J. Trace Elem. Exp. Med. 16 (2003) 269-280
21. Sakurai H., Fujisawa Y., Fujimoto S., Yasui H., and Takino T. Role of vanadium in treating diabetes. J. Trace Elem. Exp. Med. 12 (1999) 393-401
22. Sakurai H., Fujii K., Watanabe H., and Tamura H. Orally active and long-term acting insulin-mimetic vanadyl complex: bis(picolinato)oxovanadium(IV). Biochem. Biophys. Res. Commun. 214 (1995) 1095-1101
23. Fujimoto S., Fujii K., Yasui H., Matsushita R., Takada J., and Sakurai H. Long-term acting and orally active vanadyl-methylpicolinate complex with hypoglycemic activity in streptozotocin-induced diabetic rats. J. Clin. Biochem. Nutr. 23 (1997) 113-129
24. Cohen P., and Goedert M. GSK3 inhibitors: Development and therapeutic potential. Nat. Rev. Drug. Discovery. 3 (2004) 479-487
25. Adachi Y., and Sakurai H. Insulin-mimetic vanadyl(IV) complexes as evaluated by both glucose-uptake and inhibition of free fatty acid (FFA)-released in isolated rat adipocytes. Chem. Pharm. Bull. 52 (2004) 428-433
26. Kawabe K., Yoshikawa Y., Adachi Y., and Sakurai H. Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes. Life Sci. 78 (2006) 2860-2866
27. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
28. Mehdi M.Z., and Srivastava A.K. Organo-vanadium compounds are potent activators of the protein kinase B signaling pathway and potent tyrosine phosphorylation: Mechanism of insulinomimesis. Arch. Biochem. Biophys. 440 (2005) 158-164
29. 2+) chelate bis(acetylacetonate)oxovanadium(IV) potentiates tyrosine phosphorylation of the insulin receptor. J. Biol. Inorg. Chem. 10 (2005) 874-886
30. MacAulay K., Hajduch E., Blair A.S., Coghlan M.P., Smith S.A., and Hundal H.S. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur. J. Biochem. 270 (2003) 3829-3838
31. Lochhead P.L., Coghlan M., Rice S.Q.J., and Sutherland C. Inhibition of GSK3 selectively reduces glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression. Diabetes. 50 (2001) 937-946
32. Bourdeau A., Dube N., and Tremblay M.L. Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTPIB and TC-PTP. Curr. Opin. Cell Biol. 17 (2005) 203-209
33. Sakurai H., Kojima Y., Yoshikawa Y., Kawabe K., and Yasui H. Antidiabetic vanadium(IV) and zinc(II) complexes. Coord. Chem. Rev. 226 (2002) 187-198
34. Mohammad A., Sharma V., and McNeill J.H. Vanadium increases GLUT4 in diabetic rat skeletal muscle. Mol. Cell. Biochem. 233 (2002) 139-143